LB Pharmaceuticals Inc (LBRX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Ms. Heather D. Turner Esq., J.D.
|
CEO & Director | 1.02M | -- | 1973 |
|
Mr. Gad Soffer
|
Chief Operating & Business Officer | 644.8k | -- | 1977 |
|
Ms. Minako Pazdera J.D., Ph.D.
|
General Counsel | -- | -- | -- |
|
Ms. Lindsay Beaupre
|
Senior VP of People & Culture | -- | -- | -- |
|
Dr. Richard A. Silva Ph.D.
|
Senior Vice President of Technical Operations | -- | -- | 1968 |
|
Dr. James Rawls Pharm.D.
|
Senior Vice President of Regulatory Affairs | -- | -- | -- |
|
Ms. Ellen Rose
|
Senior Vice President of Corporate Affairs | -- | -- | -- |
|
Ms. Kaya Pai Panandiker Kamlesh
|
Chief Commercial Officer | -- | -- | 1977 |
|
Mr. Christopher Zergebel
|
Senior Vice President of Clinical Operations | -- | -- | -- |
|
Dr. Susan G. Kozauer M.D.
|
Chief Medical Officer | -- | -- | 1972 |
LB Pharmaceuticals Inc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 49
Description
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
November 12, 2026 at 1:30 PM UTC
LB Pharmaceuticals Inc Earnings Date
Recent Events
October 1, 2026 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
April 10, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
